PURPOSE: To calculate the actuarial risk of developing a @entity1486 (PSA) bounce after prostate brachytherapy alone, using three definitions of bounce mentioned in the literature, and to explore the relationship between disease and treatment variables and the risk of developing a bounce. The impact of PSA bounce on PSA failure was also explored. METHODS AND MATERIALS: A total of 373 @entity1 with @entity263 underwent radioactive seed implant using 125I (n = 337) or 103Pd (n = 36) without hormonal therapy or external beam RT. All @entity1 had a minimum of 1 year (median 4, maximum 11) of follow-up and at least three follow-up PSA values. PSA bounce was defined by a rise of one or two PSA values with a subsequent fall. Three definitions of bounce were used: definition 1, rise > or = 0.1 ng/mL; definition 2, rise > or = 0.4 ng/mL; and definition 3, rise >35% of previous value. RESULTS: The actuarial likelihood of experiencing a PSA bounce at 5 years was 31% for definition 1, 17% for definition 2, and 20% for definition 3. The median time to develop a bounce was 19.5 months for definitions 1 and 2 and 20.5 months for definition 3. Gleason score, initial PSA level, and clinical stage did not predict for bounce using any definition. Using definition 1, younger @entity1 (< or = 65 years) had a bounce rate at 5 years of 38% vs. 24% for older @entity1 (p = 0.009). 125I @entity1 receiving an implant dose of < or = 160 Gy had a bounce rate (definition 1) at 5 years of 24% vs. 38% for those receiving a dose delivered to 90% of the gland on the 1 month postimplant dose-volume histogram (D90) >160 Gy (p = 0.04). Using definition 2, prostate volume significantly affected the incidence of bounce. @entity1 with larger glands (>35 cm(3)) were more likely to experience a bounce (23% at 5 years) than those with smaller glands (< or = 35 cm(3)) who had a bounce rate of 11% at 5 years (p = 0.01). In a multivariate analysis of factors predicting for PSA failure, PSA bounce was not found to be significant. CONCLUSION: PSA bounce is a common phenomenon after prostate brachytherapy and occurs at a rate of 17-31%, depending on the definition used. It is more common in younger @entity1 , those receiving higher implant doses, and those with larger glands. PSA bounce does not predict for future PSA failure.

@entity1486 bounce after prostate seed implantation for XXXX : descriptions and implications.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['T1-T2 prostate cancer'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['localized prostate cancer']
